(Q72952246)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8382670%20AND%20SRC:MED&resulttype=core&format=json

30 October 2019

title

Phase II trial of recombinant interferon gamma in refractory undifferentiated carcinoma of the nasopharynx (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8382670%20AND%20SRC:MED&resulttype=core&format=json

30 October 2019

main subject

phase II clinical trial

1 reference

undifferentiated carcinoma

inferred from title

1 reference

R Mahjoubi

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8382670%20AND%20SRC:MED&resulttype=core&format=json

30 October 2019

M Bachouchi

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8382670%20AND%20SRC:MED&resulttype=core&format=json

30 October 2019

J N Munck

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8382670%20AND%20SRC:MED&resulttype=core&format=json

30 October 2019

P Busson

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8382670%20AND%20SRC:MED&resulttype=core&format=json

30 October 2019

J Gasmi

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8382670%20AND%20SRC:MED&resulttype=core&format=json

30 October 2019

N Azli

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8382670%20AND%20SRC:MED&resulttype=core&format=json

30 October 2019

M Brandely

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8382670%20AND%20SRC:MED&resulttype=core&format=json

30 October 2019

T Trusz

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8382670%20AND%20SRC:MED&resulttype=core&format=json

30 October 2019

E Cvitkovic

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8382670%20AND%20SRC:MED&resulttype=core&format=json

30 October 2019

J P Armand

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8382670%20AND%20SRC:MED&resulttype=core&format=json

30 October 2019

publication date

1 March 1993

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8382670%20AND%20SRC:MED&resulttype=core&format=json

30 October 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8382670%20AND%20SRC:MED&resulttype=core&format=json

30 October 2019

volume

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8382670%20AND%20SRC:MED&resulttype=core&format=json

30 October 2019

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8382670%20AND%20SRC:MED&resulttype=core&format=json

30 October 2019

page(s)

115-118

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8382670%20AND%20SRC:MED&resulttype=core&format=json

Lymphocyte subsets in tumour of patients with undifferentiated nasopharyngeal carcinoma: presence of lymphocytes with the phenotype of activated T cells

30 October 2019

cites work

1 reference

https://api.crossref.org/works/10.1002%2FHED.2880150206

7 January 2021

Expression of HLA-DR antigens in nasopharyngeal carcinoma: An immunohistological analysis of the tumour cells and infiltrating lymphocytes

1 reference

https://api.crossref.org/works/10.1002%2FHED.2880150206

7 January 2021

Nasopharyngeal carcinoma: a medical oncology viewpoint. The Gustave Roussy experience

1 reference

https://api.crossref.org/works/10.1002%2FHED.2880150206

7 January 2021

Cellular localization of an Epstein-Barr virus (EBV)-associated complement-fixing antigen in producer and non-producer lymphoblastoid cell lines

1 reference

https://api.crossref.org/works/10.1002%2FHED.2880150206

7 January 2021

Demonstration of Epstein-Barr virus-associated nuclear antigen in nasopharyngeal carcinoma cells from fresh biopsies

1 reference

https://api.crossref.org/works/10.1002%2FHED.2880150206

7 January 2021

Effect of human leukocyte interferon on hepatitis B virus infection in patients with chronic active hepatitis

1 reference

https://api.crossref.org/works/10.1002%2FHED.2880150206

7 January 2021

Human Leukocyte Interferon for the Treatment of Herpes Zoster in Patients with Cancer

1 reference

https://api.crossref.org/works/10.1002%2FHED.2880150206

7 January 2021

Effect of fibroblast-derived interferon administration on immune responsiveness in a patient with nasopharyngeal carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FHED.2880150206

7 January 2021

Successful treatment of nasopharyngeal carcinoma with interferon

1 reference

https://api.crossref.org/works/10.1002%2FHED.2880150206

7 January 2021

Treatment of nasopharyngeal carcinoma with human leukocyte interferon

1 reference

https://api.crossref.org/works/10.1002%2FHED.2880150206

7 January 2021

Interferons: Rationale for Clinical Trials in Neoplastic Disease

1 reference

https://api.crossref.org/works/10.1002%2FHED.2880150206

7 January 2021

Response criteria for the prostate of the USA national prostatic cancer project

1 reference

https://api.crossref.org/works/10.1002%2FHED.2880150206

7 January 2021

A phase I trial with recombinant interferon gamma (Roussel UCLAF) in advanced cancer patients

1 reference

https://api.crossref.org/works/10.1002%2FHED.2880150206

7 January 2021

Interferon gamma induced oncolysis. An effect on head and neck squamous carcinoma cultures.

1 reference

https://api.crossref.org/works/10.1002%2FHED.2880150206

7 January 2021

Differential efficacies of human type I and type II interferons as antiviral and antiproliferative agents

1 reference

https://api.crossref.org/works/10.1002%2FHED.2880150206

7 January 2021

Evidence that types I and II interferons have different receptors

1 reference

https://api.crossref.org/works/10.1002%2FHED.2880150206

7 January 2021

Preliminary trial of nonrecombinant interferon alpha in recurrent squamous cell carcinoma of the head and neck

1 reference

https://api.crossref.org/works/10.1002%2FHED.2880150206

7 January 2021

Fluorouracil and recombinant alfa-2a-interferon: an active regimen against advanced colorectal carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FHED.2880150206

7 January 2021

Potentiation of cisplatin by alpha-interferon in advanced non-small cell lung cancer (NSCLC): a phase II study

1 reference

https://api.crossref.org/works/10.1002%2FHED.2880150206

7 January 2021

Identifiers

DOI

10.1002/HED.2880150206

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8382670%20AND%20SRC:MED&resulttype=core&format=json

30 October 2019

1 reference